| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/03/2011 | US20110048980 Fatty Acid Oxidation Inhibitors Treating Hyperglycemia and Related Disorders |
| 03/03/2011 | DE102009039191A1 Preparing substance, useful e.g. for treating physical illness, preferably prostate illness, comprises stirring peeled, sterilized and ground wheat grains in boiling water, incubating with microorganisms, and fermenting obtained suspension |
| 03/03/2011 | DE102009038950A1 Neue antiparasitäre Kombination von Wirkstoffen New antiparasitic combination of active ingredients |
| 03/03/2011 | DE102009038949A1 Neue Verwendung von heterocyclisch substituierten 1,2,4-Triazindionen New use of heterocyclic substituted 1,2,4-triazinediones |
| 03/03/2011 | DE102009029010A1 Antimikrobielle Etherguanidine Antimicrobial Etherguanidine |
| 03/03/2011 | DE102008030091B4 Uracilderivate und deren Verwendung Uracil derivatives, and their use |
| 03/03/2011 | CA2808277A1 Novel colchicine derivatives, methods and uses thereof |
| 03/03/2011 | CA2793090A1 Sphingosine type 1 inhibitors and methods for making and using same |
| 03/03/2011 | CA2790390A1 Novel tetrahydroisoquinoline compounds |
| 03/03/2011 | CA2772634A1 Use of cannabidiol prodrugs in topical and transdermal administration with microneedles |
| 03/03/2011 | CA2772610A1 Sdf-1 delivery for treating ischemic tissue |
| 03/03/2011 | CA2772575A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | CA2772499A1 Polymorphic forms of manidipine |
| 03/03/2011 | CA2772489A1 Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders |
| 03/03/2011 | CA2772386A1 Tetracycline compounds |
| 03/03/2011 | CA2772316A1 1h-pyrazolo [3,4-b] pyridine compounds for inhibiting raf kinase |
| 03/03/2011 | CA2772301A1 Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| 03/03/2011 | CA2772294A1 Methods for the prevention and treatment of cerebral ischemia |
| 03/03/2011 | CA2772169A1 (thio)morpholine derivatives as s1p modulators |
| 03/03/2011 | CA2772168A1 Anhydrate forms of a pyridine derivative |
| 03/03/2011 | CA2772164A1 Heterocyclic-substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof |
| 03/03/2011 | CA2772102A1 Conjugates of pyrrolo[1,4] benzodiazepine dimers as anticancer agents |
| 03/03/2011 | CA2772093A1 Np-1 antagonists and their therapeutic use |
| 03/03/2011 | CA2772085A1 Compounds that treat malaria and prevent malaria transmission |
| 03/03/2011 | CA2772074A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | CA2772071A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | CA2772036A1 Targeting pax2 for the treatment of breast cancer |
| 03/03/2011 | CA2771992A1 Kinase inhibitors |
| 03/03/2011 | CA2771939A1 Methylpyrrolopyridinecarboxamides |
| 03/03/2011 | CA2771938A1 Methylpyrrolopyrimidinecarboxamides |
| 03/03/2011 | CA2771936A1 Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
| 03/03/2011 | CA2771933A1 Bisphosphonates as inhibitors of acid sphingomyelinase |
| 03/03/2011 | CA2771895A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | CA2771893A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | CA2771890A1 Condensed quinolines as protein kinase modulators |
| 03/03/2011 | CA2771871A1 Pharmaceutical compositions comprising prednisolone metasulfobenzoate and 5-asa for treating ibd |
| 03/03/2011 | CA2771833A1 Fused heterocyclic ring derivative and use thereof |
| 03/03/2011 | CA2771807A1 Treatment of macular degeneration |
| 03/03/2011 | CA2771789A1 Combination therapy for treating proliferative diseases |
| 03/03/2011 | CA2771775A1 Compounds and compositions as protein kinase inhibitors |
| 03/03/2011 | CA2771673A1 Compounds and compositions as protein kinase inhibitors |
| 03/03/2011 | CA2771601A1 Morpholinone compounds as factor ixa inhibitors |
| 03/03/2011 | CA2771044A1 Aralkyl benzyl ethers compounds, process for preparation thereof, intermediate compounds, use of such compounds, methods of treatment and/or prevention, pharmaceutical compositionand medicine containing the same |
| 03/03/2011 | CA2770866A1 Cannabinoid receptor modulators |
| 03/03/2011 | CA2770778A1 Pharmaceutical composition for preventing or treating rheumatoid arthritis containing rebamipide |
| 03/03/2011 | CA2770695A1 Synthesis of oxygen carrying, turbulence resistant, high density submicron particulates |
| 03/03/2011 | CA2770480A1 Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| 03/03/2011 | CA2770475A1 Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
| 03/03/2011 | CA2769289A1 Development of universal cancer drugs and vaccines |
| 03/03/2011 | CA2769151A1 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors |
| 03/03/2011 | CA2768651A1 Particulate composition and pharmaceutical composition containing the same |
| 03/03/2011 | CA2767901A1 Carbocyclic glyt1 receptor antagonists |
| 03/03/2011 | CA2767770A1 Pyrrolidine derivatives as nk3 receptor antagonists |
| 03/02/2011 | EP2290081A2 IL-17 homologous polypeptide and therapeutic uses thereof |
| 03/02/2011 | EP2290078A2 Immunostimulatory nucleic acids |
| 03/02/2011 | EP2290063A1 Sirna of human osteopontin |
| 03/02/2011 | EP2290055A2 Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications |
| 03/02/2011 | EP2289970A1 Biocompatible polymers, their process of manufacture and compositions containing them |
| 03/02/2011 | EP2289941A2 Administration of agents for the treatment of inflammation |
| 03/02/2011 | EP2289911A2 Therapeutic use of a growth factor, NsG33 |
| 03/02/2011 | EP2289904A1 Inhibitors of microbial infections |
| 03/02/2011 | EP2289900A1 Bisphosphonates as inhibitors of acid sphingomyelinase |
| 03/02/2011 | EP2289894A2 Pyrrolo-triazine compounds useful as kinase inhibitors |
| 03/02/2011 | EP2289893A1 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| 03/02/2011 | EP2289892A1 Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer |
| 03/02/2011 | EP2289891A2 Novel polyquinoline derivates and the therapeutic use thereof |
| 03/02/2011 | EP2289883A1 Novel FXR (NR1H4) binding and activity modulating compounds |
| 03/02/2011 | EP2289882A1 3-oxopiperazinium derivatives as agonists of nerve growth factor and their use as medicaments |
| 03/02/2011 | EP2289879A1 Synthesis of a crytalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt |
| 03/02/2011 | EP2289878A1 Fexofenadine polymorphs and process for the preparation thereof |
| 03/02/2011 | EP2289876A1 Bis(thio-hydrazide amide) compounds in combination with taxol for treating cancer |
| 03/02/2011 | EP2289872A2 Selective androgen receptor modulators and medical uses thereof |
| 03/02/2011 | EP2289871A1 7-substituted tetracycline compounds |
| 03/02/2011 | EP2289868A1 Carboxylic acid compound |
| 03/02/2011 | EP2289848A2 Therapeutic malonic acid/acetic acid C60 tri-adducts of Buckminsterfullerene and methods related to thereto |
| 03/02/2011 | EP2289564A2 Derivatives of aniline as precursors for F18-labeling |
| 03/02/2011 | EP2289556A2 Pharmaceutical composition for use in treatment of diabetes |
| 03/02/2011 | EP2289554A1 Compositions comprising thalidomide and artemisinin for the treatment of cancer |
| 03/02/2011 | EP2289552A1 An immunosuppressive agent plus anti-TCR antibodies for the induction of chimerism in transplantation |
| 03/02/2011 | EP2289551A1 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 03/02/2011 | EP2289549A2 Immunoconjugates for treating cancer |
| 03/02/2011 | EP2289543A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
| 03/02/2011 | EP2289531A2 Medicaments for increasing endogenous erythropoietine (EPO) |
| 03/02/2011 | EP2289524A1 Facially amphiphillic polymers as anti-infective agents |
| 03/02/2011 | EP2289523A2 Regimens for intra-articular viscosupplementation |
| 03/02/2011 | EP2289522A1 Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer |
| 03/02/2011 | EP2289521A2 Compositions and methods for use in tergeting vascular destruction |
| 03/02/2011 | EP2289520A1 Use of acetylsalicylic acid for the prophylaxis and/or treatment of influenza virus infection. |
| 03/02/2011 | EP2289519A2 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| 03/02/2011 | EP2289518A1 Therapeutic agent for inflammatory bowel disease |
| 03/02/2011 | EP2289517A2 Controlled release oxycodone compositions |
| 03/02/2011 | EP2289516A1 Methods and means for the treatment of HPV induced intraepithelial neoplasias |
| 03/02/2011 | EP2289515A2 Combinations comprising a diaryl urea and an interferon |
| 03/02/2011 | EP2289514A1 Pramipexole once daily dosage form |
| 03/02/2011 | EP2289513A2 Method for decreasing the blood glucose level in mammals |
| 03/02/2011 | EP2289512A1 Pharmaceutical foam |
| 03/02/2011 | EP2289511A1 Use of retinoids for treatment or prevention of Alzheimer's Disease |
| 03/02/2011 | EP2289510A1 Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| 03/02/2011 | EP2289509A2 Methods for purifying trans-(-)-delta9-tetrahydrocannabinol and trans-(+)-delta9-tetrahydrocannabinol |
| 03/02/2011 | EP2289508A1 Combined treatment for lung cancer |